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Abstract
In vitro testing alone is no longer considered sufﬁcient evidence presented solely with respect to drug
release and permeation testing. These studies are thought to bemore reliable and representative when
using tissue or animalmodels; as opposed to syntheticmembranes. The release of anti-glaucoma drug
timololmaleate from electrically atomised coatings was assessed here using freshly excised bovine
corneal tissue. Electrohydrodynamic processingwas utilised to engineer functionalised ﬁbrous
polyvinylpyrrolidone-Poly (N-isopropylacrylamide) coatings on the outer side of commercial silicone
contact lenses. Benzalkonium chloride, ethylenediaminetetraacetic acid, Brij® 78 and borneol were
employed as permeation enhancers to see their effect on ex vivo permeation of timololmaleate
through the cornea. Formulations containing permeation enhancers showed a vast improvement with
respect to cumulative amount of drug permeating through the cornea as shown by a six fold decrease
in lag time compared to enhancer-free formulations.Most drug delivery systems require the drug to
pass or permeate through a tissue or biologicalmembrane. This study has shown that to fully
appreciate and understand how anovel drug delivery systemwill behave not onlywithin the device but
with the external environment or tissue, it is imperative to have in vitro and ex vivo data in
conjunction.
Introduction
The ability to achieve controlled and/or sustained ocular drug delivery is a constant challenge faced by research
scientists [1, 2].Whilstmore conventional dosage forms such as eye drops boast ease of formulation, there is the
issue of eyemicro-structure serving as a barrier. Due to the complexity of the organ, sufﬁcient therapeutic drug
levels are difﬁcult to achieve consequently leading to low bioavailability and frequent administration [1].
Despite efforts to improve drug bioavailability from a formulation view point (e.g. increasing viscosity [3],
forming complexes with cyclodextrins [4, 5]), the issue of sustaining drug delivery is still prominent. As a result,
novel approaches have been introducedwhich include the use of ocular devices as drug reservoirs [2]. Themost
common concept to emerge from this are contact lenses.More commonly used for vision correction, contact
lenses havemore recently found to act as successful drug delivery devices, achieving controlled and sustained
active delivery. The use of these removable implants increases retention time of the drug in the pre-corneal
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The aimof this studywas to develop and characterise nano-coatings for contact lenses with the view to
achieve the sustained release of anti-glaucoma drug timololmaleate (TM). The research and development sector
of pharmaceutics is constantly evolving; building on and updating existingmethods used in this remit.Whilst
there is a focus on in vitro testing of ocular formulations with respect to release and permeation, this alone is no
longer considered sufﬁcient characterisation [6]. In vitro testing involvesmeasuring the release of an active drug
fromamatrix in an environment simulating physiological conditions (37 °C, pH7.4). Regardless of the ability to
characterise drug release without using animals, the dialysismembrane used in vitro release testingmay not be an
adequate layer tomimic biological tissue. As such, it is vital to conduct in vitro drug release and ex vivo studies are
vital in conjunction in order to arrive atmore accurate conclusions. Quantifying the rate of drug permeation
through a biologicalmembrane is vital, as its impact is key in the absorption and distribution of the
released drug.
Electrohydrodynamic atomisation (EHDA), more speciﬁcally electrospinningwas utilised in this instance to
engineerﬁbrous coatings for contact lens surfaces. The on-demand, cost effective process has already shown its
potential in an array of applications [7] includingwoundmanagement [8–13], drug delivery [14–22]
bioengineering [23–26] and theranostics [27]. Here, electrospun ﬁbrous coatings were engineered to assess the
ex vivo release and permeation of TM through freshly excised cornea as an extension of previous work [18]. The
effectiveness of four different permeation enhancers in increasing TMpermeation through bovine corneawas
evaluated.
Materials
Polyvinylpyrrolidone (PVP) (4.4×104 g mol−1)was obtained fromAshland,Worcestershire, United
Kingdom. Poly (N-isopropylacrylamide) (PNIPAM) (2–4×104 g mol−1), ethanol, TM, benzalkonium
chloride (BAC), ethylenediaminetetraacetic acid (EDTA), Brij® 78 and borneol were all purchased fromSigma
Aldrich,Dorset, United Kingdom. All reagents usedwere of analytical grade.
Methods
Solution preparation
Solutions containing PVP and PNIPAM (now referred to as composite) at 50:50 ratio to achieve 5%w/v
solutionswere prepared by dissolving the polymers in ethanol bymechanical stirring for 30 min at ambient
temperature (23 °C). Twodifferent TMconcentrations (5%w/wand 15%w/wof the polymerweight)were
prepared using this stock solution. These base solutionswere then used to prepare further formulations each
containing a different permeation enhancer. Table 1 shows theﬁnal composition of the 8 solutions prepared for
this study.
Coating engineering
These solutionswere processed using EHDA,more speciﬁcally the electrospinning process. A schematic
diagramof the set-up can be seen inﬁgure 1. The solutionswere drawn into 5 ml syringes thatwere attached to a
syringe infusion pump. The pump allowed controlled ﬂowof liquid through the electrospinning set-up. The
solutionwas fed through silicone tubing to a conductive stainless steel needle; whichwas attached to a high
power voltage supply. All atomisation processes were carried out in ambient conditions. The resulting coatings
wereﬁrst collected onmicroscope slides for pilot studies then subsequently onto dehydrated commercial
Table 1.Composition of each electrohydrodynamically processed formulation. Each formulation contained PVP and PNIPAMat a 50:50
ratio to achieve 5%w/v polymeric solutions.
Formulation
Timololmaleate concentration (%w/wof the
polymer) Permeation enhancer
Permeation enhancer concentration (%
w/v)
Composite-TM 5 — —
F1 5 BAC 0.01
F2 5 EDTA 0.5
F3 5 Brij® 78 0.1
F4 5 Borneol 1
F5 15 BAC 0.01
F6 15 EDTA 0.5
F7 15 Brij® 78 0.1
F8 15 Borneol 1
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PureVision BalaﬁlconA silicone contact lenses, sourced fromBausch and Lomb,NewYork,United States of
America. Controlled deposition of the coatings was achieved using a lens holder, which could accommodate up
to four lenses. To establish theweight of the coatings, the lenses were weighed before and after deposition. All
engineering processes were carried out at ambient temperature (23 °C±0.5 °C).
Drug encapsulation efﬁciency (EE)
Todetermine TMEE,weighed coatings samples were dissolved in ethanol for 1week. UV spectroscopy
(λ=295 nm)was used to determine the amount of drug loaded into the coatings. Equation (1)was used to
calculate EE
= - ( )EE Drug Added Free Drug
Drug Added
. 1
Calculating the amount of drug that is present within the atomised coatings aids the analysis of subsequent
ex vivo testing.
Ex vivo testing
TMrelease from the atomised coatings and permeation through freshly excised bovine corneawas studied using
vertical diffusion cells. The corneaswere excised from fresh bovine eyes andwere consequently ﬁxed between
the receptor and donor compartment. The eyes were ﬁrst examined for any corneal damage before dissection to
obtain the corneawith a 2 mm sclera border to preserve corneal structure. The cornea-scleral tissuewaswashed
with PBS andmounted in between glass donor compartment (surface area=1.77 cm2) and receptor
compartmentwith the corneal endothelium facing the latter. The receptor wasﬁlledwith 12 ml of PBS and
contained aminimagnetic stirrer to ensure constant stirring. The temperature of the glass cells wasmaintained
at 37 °Cvia a heating block. At pre-determined times, 400 μl of receptormediumwas removed from the
receptor compartment and replacedwith fresh PBS of equal volume. Cumulative drug permeationwas analysed
usingUV spectroscopy (λ=295 nm). The cumulative amount of timololmalate permeating through the




Previouswork carried out in this area [17, 18] has already showed the novel lens holder used herewas able to
accommodate up to 4 lenses whilst keeping the lenses stable and stationary during the deposition process. A
masked armwas used to ensure only the peripheral regions of the lenses were coated so as not to obstruct vision.
Figure 2(a) shows an uncoated dehydrated lens whileﬁgure 2(b) shows amodel-coated lens with a central region
void of the deposited coating. Theﬁnewhitemist on the latter shows the outer side (pre-corneal region) coated
Figure 1.A schematic diagram exhibiting the key components of the electrohydrodynamic atomisation process.
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with the electrospun ﬁbrousmatrix. Scanning electronmicroscopy images showed the coatings were
characteristicallymade up of smooth, non-featured nanoﬁbers (ﬁgure 2(c)).
TMEE andﬁbre composition
Whilst table 1 shows the constituents thatmake up the formulations and their concentrations, table 2 displays
theﬁbre composition; i.e. what percentage of each coating is taken up by each component, based on drug EE.
Evidently, the differences in percentage here are solely due to the EE and the concentration of permeation
enhancer. The highest EEwas foundwith F7, with almost all of the loaded drug (99.7%) being encapsulated
within thematrix and the lowest with F4 (51.75%). For both drug loadings (5%w/wand 15%w/w), it seems the
highest encapsulationwas achievedwith formulations containing borneol, as seen in table 2.
Ex vivo permeation testing
Figure 3 shows the permeation of TM through freshly excised bovine cornea following release from the
electrospun permeation enhancer-loaded coatings; with table 3 summarising the parameters derived from these
ex vivo studies. A lag time of 30 minwas deciphered for all eight formulations. This temporalmeasurement is
quantiﬁed here as the time taken for the drug to diffuse/move through the spun polymermatrix of the coating
and through the cornea before released into the releasemedium in the receptor compartment. This was a six-
Figure 2.Digital images of (a)uncoated lens, (b) a lenswith a typical electrospun coating, (c) SEM image of a typical electrically
atomised coating at×50kmagniﬁcation.
Table 2. Fibre composition and drug encapsulation efﬁciency of each electrically atomised coating.
Theoretical ﬁbre composition
Formulation Polymer (%w/w) Timololmaleate (%w/w) Permeation enhancer (%w/w) Drug encapsulation efﬁciency (%)
F1 95.05 4.75 0.2 92.21
F2 89.96 4.35 8.69 60.92
F3 93.45 4.67 1.88 93.11
F4 80 4 16 51.75
F5 86.81 13.02 0.17 70.74
F6 80 12 8 57.01
F7 85.47 12.82 1.71 99.7
F8 74.1 11.1 14.8 82.45
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fold decrease from the lag time calculated for permeation-free coating; highlighting the fact that the proposed
reasoning for incorporating the permeation enhancers was successful. The lag time of drug permeationwas
reduced; givingmore controlled and faster drug permeation.
The cumulative amount of drug permeated achievedwith permeation enhancer free coatings was
approximately 53.39±3.95 μg cm−2 after 24 h, the lowest of all 9 formulations (ﬁgure 3). Regardless of
speciﬁcity of permeation enhancer, the incorporation of the additives increased the total of drug permeated
through the cornea. Formulations containing EDTA (F2 and F6), showed to have the lowest amount of drug
permeated per area after 24 h. This could be attributed to these formulations existing as suspensions before
Figure 3.Ex vivo cumulative amount of timololmaleate permeated across freshly excised bovine cornea for initial timololmaleate
loading of (a) 5%w/wand (b) 15%w/w.
Table 3. Summary of parameters derived from in vitro and ex vivo studies.
Formulation








Composite-drug 68.25±1.63 0.057±0.017 0.012±0.0038 180
F1 84.63±1.99 0.076 12±0.017 0.017±0.0039 30
F2 83.92±2.08 0.098±0.010 0.037±0.0038 30
F3 81.49±5.38 0.104±0.010 0.038±0.0087 30
F4 80.28±1.80 0.101±0.0058 0.049±0.0027 30
F5 84.83±3.78 0.057±0.0042 0.0084±0.0027 30
F6 81.94±2.68 0.074±0.0044 0.006 13±0.000 37 30
F7 86.72±3.09 0.098±0.0088 0.011±0.000 95 30
F8 77.33±8.14 0.059±0.0099 0.0048±0.000 81 30
a Values aremean± standard deviation.
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electrohydrodynamic processing. EDTA is not soluble in ethanol and hence stayed particulate in F2 and F6.
These EDTAparticlesmay act as additional diffusional barriers, hindering themovement of TM through the
polymericmatrix and the cornealmembrane.
A study carried out by Burgalassi et al found that BAC, EDTA andBrij® 78 all found to enhance the
permeation of timolol by 3.06, 1.63 and 1.16 fold, respectively, with BACbeing themost active enhancer [28].
Similar results were found in the present study; with formulations containing BAC achieving highest amount of
TMpermeated through the cornea per area (5%w/wdrug loading: 97.6 μg cm−2 and 15%w/w: 146.8 μg cm−2).
The inﬂuence of borneol has been previously assessed on in vitro release and permeation of hydrophilic
quinolone antibiotic oﬂoxacin. It was found the incorporation of the naturally occurring compound resulted in
a 2.15 fold increase in the release of the antibiotic [29]. Borneol has also found to enhance the permeability of the
blood-ocular barrier to dye Evan’s Blue [30] suggesting its use as a useful penetration enhancer in ophthalmic
drug delivery. Its use in these electrically atomised coatings alsomirror these results: the amount of TM
permeating through the cornea is greatly increased compared to enhancer-free coatings. A permeability
coefﬁcient higher than 20× 10−6 cm2 h−1 (as seen herewith F0–F8) is indicative of high/good permeability.
The evidence collated from in vitro probe release showing the atomised coatings does not detach from the lens
shows there is increased contact timewith the corneal surface in the pre-corneal region. This alongwith the
hydrophilicity of TMand the excipients used (i.e. the permeation enhancers) aided the release and permeation
of TM through the cornea at amuchmore sustained rate thanwithout the enhancer additives. These values are
considerably lower than that of commercial eye drops (20.458 μg cm−2 h−1) [31] showing these electrospun
coatings on contact lenses delayed TM transport through the cornealmembrane. This permits for less frequent
dosing and hence reduces the risks of systemic absorption and ocular toxicity associatedwith high drug loading.
As expected, the amount of TM released and permeated from F5 to F8was a lot higher than their lower drug
loading counterparts. This, however, contradicts the results foundwith in vitro drug release studies (table 3). The
drug loading did not affect the cumulative percentage release of TM; however, there is an evident difference with
ex vivo permeation studies. This could be a direct result of the fact that the cellophane dialysismembranemay
not an adequatemembrane tomimic biologicalmembrane. It is because of this in vitro drug release and ex vivo
studies are vital to conduct in conjunction to get amore accurate conclusion.
Conclusion
By utilising a speciﬁc combination of polymers and permeation enhancers, this study has assessed and shown the
potential of using EHDA to engineer robust coatings for contact lenses to increase drug permeation through the
cornea and consequently improving ocular drug bioavailability. The ex vivo studies showed a vast improvement
with respect to timololmaleate permeation upon the addition of permeation enhancers compared to additive-
free formulations. This increase in drug permeation over amore appropriate time frame has the potential to
minimise ocular toxicity due to less being absorbed systemically. Combining novel engineering techniques like
EHDAand an already established drug delivery device has shown great prospects in personalised ocular drug
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